Can Fite BioPharma Ltd (CANF)

[midastouch017]

Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston

https://finance.yahoo.com/news/fite-participate-licensing-distribution-partnering-110000323.html

PETACH TIKVA, Israel, June 02, 2023--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology, inflammatory and liver diseases, today announced its VP of Business Development, Dr. Sari Fishman, will participate in numerous partnering meetings at the Bio International Convention in Boston, Massachusetts on June 5-8, 2023.

Can-Fite currently has out-licensing and distribution deals with six pharma companies across North America, Europe, and Asia, which include upfront and milestone payments. The Company’s growing slate of indications and advanced pipeline are attracting increased interest from additional potential partners. Focusing on its core expertise in clinical development, Can-Fite pursues a strategy of partnering with companies in specific geographic markets that specialize in pharmaceutical distribution and regional regulatory approval.

Can-Fite’s pipeline of indications includes:

Psoriasis

Headed into pivotal Phase 3 market registration trial

Liver Cancer

Pivotal Phase 3 market registration trial

NASH

Phase 2b

Pancreatic Cancer

Headed into Phase 2a

Erectile Dysfunction

Preclinical

Cannabinoids

Preclinical

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's anti-inflammatory drug Piclidenoson reported topline results in a Phase 3 trial for psoriasis and is expected to commence a pivotal Phase 3. Can-Fite's cancer and liver drug, Namodenoson, is being evaluated in a Phase 2b trial for the treatment of non-alcoholic steatohepatitis (NASH), enrollment is expected to commence in a Phase 3 trial for hepatocellular carcinoma (HCC), and the Company is planning a Phase 2a study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date. For more information please visit: www.can-fite.com.